PATTERNS OF METHAMPHETAMINE USE AND ITS ASSOCIATIONS WITH PSYCHIATRIC SYMPTOMS IN PATIENTS UPON ADMISSION AT THE NATIONAL REHABILITATION CENTER LIDO BOGOR, INDONESIA
Keywords:Addiction severity index (ASI), Methamphetamine, Narcotics, Rehabilitation, Substance abuse
Objective: Methamphetamine (MA) is a substance that is heavily abused worldwide. This present study aimed to investigate the association between the patterns of methamphetamine use and psychiatric symptoms in patients upon admission at The National Rehabilitation Center, Lido Bogor.
Methods: This was a cross-sectional study of MA abusers during the period of January 2016–December 2018 at The National Rehabilitation Center, Lido, Bogor. This study was done by assessing medical records. The inclusion criteria were MA abusers at the age of 18 y and above. Assessment of psychiatric symptoms was evaluated using Addiction Severity Index (ASI). Microsoft Excel and SPSS version 22.0 were used to process the data.
Results: The inclusion criteria were fulfilled by 1842 MA abusers. We found that 770 (41.8%) of MA abusers were assessed with psychiatric symptoms according to ASI. Depression was the most prevalent psychiatric symptom (31.9%), followed by anxiety (24.5%), and psychosis (8.9%). According to the results of multivariate analysis, the demographic profile and the mode of MA administration that are associated with the psychiatric symptoms were: female [odds ratio (OR): 1.95; 95% confidence interval (CI): 1.25–2.96, p<0.001], 5-year duration of use [OR 1.43; 95% CI: 1.43 (1.19–1.73), p<0.001], smoking as the route of administration [OR 1.3; 95% CI: 1.08–1.56, p<0.001, p = 0.006], and concomitant use with other narcotics [OR 1.76; 95% CI: 1.46–2.13, p<0.001].
Conclusion: Among MA abusers admitted to The National Rehabilitation Center, the main factors associated with psychiatric symptoms were: female, long duration of use, smoking as the route of administration, and concomitant use with other narcotics.
UNODC. UNO on D and C. Stimulants. 2019. Word Drug Report; 2019.
Badan narkotika nasional republik indonesia. Infografis survei prevalensi penyalahgunaan narkoba tahun; 2020.
BNN RI. Jurnal data puslitdatin tahun. J Data Puslidatin. 2018:240.
Cruickshank CC, Dyer KR. A review of the clinical pharmacology of methamphetamine. Addiction. 2009;104(7):1085-99. doi: 10.1111/j.1360-0443.2009.02564.x, PMID 19426289.
Ma J, Sun XJ, Wang RJ, Wang TY, Su MF, Liu MX. Profile of psychiatric symptoms in methamphetamine users in China: greater risk of psychiatric symptoms with a longer duration of use. Psychiatry Res. 2018;262:184-92. doi: 10.1016/j.psychres.2018.02.017, PMID 29453037.
Sulaiman AH, Said MA, Habil MH, Rashid R, Siddiq A, Guan NC. The risk and associated factors of methamphetamine psychosis in methamphetamine-dependent patients in Malaysia. Compr Psychiatry. 2014;55Suppl 1:S89-94. doi: 10.1016/ j.comppsych.2013.01.003, PMID 23433219.
Wang L, Min JE, Krebs E, Evans E, Huang D, Liu L. Polydrug use and its association with drug treatment outcomes among primary heroin, methamphetamine, and cocaine users. Int J Drug Policy. 2017;49:32-40. doi: 10.1016/j.drugpo.2017.07.009, PMID 28888099.
Hart CL, Gunderson EW, Perez A, Kirkpatrick MG, Comer SD, Foltin RW. Methamphetamine in Humans. 2016;33(8):1847-55.
Bujarski S, Roche D, Lunny K, Moallem NR, Courtney KE, Allen V. A community sample of methamphetamine users. 2015;127-32.
Su MF, Liu MX, Li JQ, Lappin JM, Li SX, Wu P. Epidemiological characteristics and risk factors of methamphetamine-associated psychotic symptoms. Front Psychiatry. 2018;9:489. doi: 10.3389/fpsyt.2018.00489, PMID 30369888.
Rungnirundorn T, Verachai V, Gelernter J, Malison RT, Kalayasiri R. Sex differences in methamphetamine use and dependence in a thai treatment center. J Addict Med. 2017;11(1):19-27. doi: 10.1097/ADM.0000000000000262. PMID 27649265.
Dimiceli LE, Sherman SG, Aramrattana A, Sirirojn B, Celentano DD. Methamphetamine use is associated with high levels of depressive symptoms in adolescents and young adults in rural chiang mai province, Thailand. BMC Public Health. 2016;16(1):1-9. doi: 10.1186/s12889-016-2851-1.
Salo R, Flower K, Kielstein A, Leamon MH, Nordahl TE, Galloway GP. Psychiatric comorbidity in methamphetamine dependence. Psychiatry Res. 2011;186(2-3):356-61. doi: 10.1016/j.psychres.2010.09.014, PMID 21055832.
Bao YP, Qiu Y, Yan SY, Jia ZJ, Li SX, Lian Z. Pattern of drug use and depressive symptoms among amphetamine-type stimulants users in Beijing and G. Province, China. PLOS One. 2013;8(4):e60544. doi: 10.1371/journal.pone.0060544, PMID 23585838.
Lamyai W, Pono K, Indrakamhaeng D, Saengsin A, Songhong N, Khuwuthyakorn P. Risks of psychosis in methamphetamine users: a cross-sectional study in Thailand. BMJ. 2019;9(10):e032711. doi: 10.1136/bmjopen-2019-032711, PMID 31615802.
Zweben JE, Cohen JB, Christian D, Galloway GP, Salinardi M, Parent D. Psychiatric symptoms in methamphetamine users. Am J Addict. 2004;13(2):181-90. doi: 10.1080/10550490490436055, PMID 15204668.
Rigoni R, Woods S, Breeksema JJ. From opiates to methamphetamine: building new harm reduction responses in Jakarta, Indonesia. Harm Reduct J. 2019;16(1):67. doi: 10.1186/s12954-019-0341-3, PMID 31829253.
Jones CM, Compton WM, Mustaquim D. Patterns and characteristics of methamphetamine use among adults-United States, 2015-2018. MMWR Morb Mortal Wkly Rep. 2020;69(12):317-23. doi: 10.15585/mmwr.mm6912a1, PMID 32214077.
Hellem TL. A review of methamphetamine dependence and withdrawal treatment: A focus on anxiety outcomes. J Subst Abuse Treat. 2016;71:16-22. doi: 10.1016/j.jsat.2016.08.011, PMID 27776672.
Su H, Zhang J, Ren W, Xie Y, Tao J, Zhang X. Anxiety level and correlates in methamphetamine-dependent patients during acute withdrawal. Medicine (Baltimore). 2017;96(15):e6434. doi: 10.1097/MD.0000000000006434, PMID 28403074.
Burdzovic Andreas J, Lauritzen G, Nordfjaern T. Co-occurrence between mental distress and poly-drug use: A ten year prospective study of patients from substance abuse treatment. Addict Behav. 2015;48:71-8. doi: 10.1016/j.addbeh.2015.05.001, PMID 26004857.
Ware OD, Manuel JI, Huhn AS. Adults with opioid and methamphetamine co-use have lower odds of completing short-term residential treatment than other opioid co-use groups: a retrospective health services study. Front Psychiatry. 2021;12:784229. doi: 10.3389/fpsyt.2021.784229. PMID 34955930.
Palmer A, Scott N, Dietze P, Higgs P. Motivations for crystal methamphetamine-opioid co-injection/co-use amongst community-recruited people who inject drugs: A qualitative study. Harm Reduct J. 2020;17(1):14. doi: 10.1186/s12954-020-00360-9, PMID 32106854.
How to Cite
Copyright (c) 2022 ROHMANIKA, WAWAIMULI AROZAL, MELVA LOUISA, ANGGI GAYATRI, ARIA KEKALIH, JEFMAN EFENDI MARZUKI HY, ERNIAWATI LESTARI, DIAH SETIA UTAMI
This work is licensed under a Creative Commons Attribution 4.0 International License.